Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease.

@article{OCaoimh2014EffectsOC,
  title={Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease.},
  author={R. O’Caoimh and L. Healy and Y. Gao and A. Svendrovski and D. Kerins and J. Eustace and P. Kehoe and G. Guyatt and D. Molloy},
  journal={Journal of Alzheimer's disease : JAD},
  year={2014},
  volume={40 3},
  pages={
          595-603
        }
}
BACKGROUND Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are associated with reduced rates of cognitive decline in patients with dementia. CACE-Is may also improve exercise tolerance in functionally impaired older adults with normal cognition, suggesting that CACE-Is may positively influence activities of daily living (ADL) in dementia. OBJECTIVE To compare rates of decline in patients with mild to moderate Alzheimer's disease (AD) receiving CACE-Is to those not… Expand
Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease
TLDR
In people with Alzheimer's disease receiving acetylcholinesterase inhibitors, those also taking C-ACEIs had stronger initial improvement in cognitive function, but there was no evidence of longer-lasting influence on dementia progression. Expand
Renin-Angiotensin-System Modulation may slow the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Antihypertensives that modulate the renin-angiotensin system (RAS) on AD conversion in those with MCI has not been explored. Evidence suggests that blood-brain-barrier (BBB) permeability is necessaryExpand
Renin Angiotensin aldosterone system inhibition in controlling dementia-related cognitive decline.
TLDR
Current evidence is limited to preclinical and observational studies such that there is now a pressing need to confirm preliminary studies with properly conducted randomized control trials. Expand
Can Angiotensin-Converting Enzyme Inhibitors Slow the Progression of Cognitive Decline In Elderly Patients With Dementia?
TLDR
A systematic review of the current research on ACE-I use in cognitive decline found conflicting research and new discoveries into the pathophysiology of the brain and ACE. Expand
The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases
TLDR
A number of small molecule AngIV-based compounds that are metabolically stable, penetrate the blood-brain barrier, and facilitate compromised memory and motor systems are synthesized along with details concerning a recently synthesized molecule, Dihexa that shows promise in overcoming memory andMotor dysfunctions by augmenting synaptic connectivity via the formation of new functional synapses. Expand
Effect of Visit-to-Visit Blood Pressure Variability on Cognitive and Functional Decline in Mild to Moderate Alzheimer's Disease.
TLDR
This observational study does not support recent research showing that VVV predicts cognitive decline in AD, and further studies are needed to clarify its effects on ADL in AD. Expand
Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system.
TLDR
Initial evidence with AD patients shows that a brain-penetrating ACE inhibitor counteracts the process of neurodegeneration and dementia, and centrally acting ACE inhibitors given in addition to the standard therapy, cholinesterase inhibition, can improve cognitive function of AD patients for several months. Expand
Angiotensin converting enzyme serum activities: Relationship with Alzheimer’s disease
TLDR
ACE serum activity that correlates with age is likely to constitute a potential risk factor for the development of AD and might be a useful biomarker for disease status with increasingly high ACE from mild stage to moderate-severe stage. Expand
The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status
TLDR
Among APOE ε4 non-carriers with AD, ARB use was associated with greater preservation of memory and attention/psychomotor processing speed, particularly compared to ACE-Is that do not cross the blood-brain-barrier. Expand
Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis
TLDR
RASB antihypertensive drugs may be potential treatments for reducing the incidence of dementia, but ARBs use is likely to be analogous to ACEIs, with CACEIs being effective. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 94 REFERENCES
Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia
TLDR
Cognitive scores may improve in the first 6 months after Cace-I treatment and use of CACE-Is is associated with a reduced rate of cognitive decline in patients with dementia. Expand
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study.
TLDR
While ACE inhibitors as a class do not appear to be independently associated with dementia risk or cognitive decline in older hypertensive adults, there may be within-class differences in regard to these outcomes. Expand
Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging
TLDR
Within-class differences linked to different chemical structures and/or drug potencies may exist, with a possible effect of the enalapril and lisinopril sub-groups in reducing the risk of incident MCI in older hypertensive adults. Expand
The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial.
TLDR
In this study, ramipril therapy inhibited CSF ACE activity and improved blood pressure, but did not influence CSF Aβ1-42, while larger trials are needed to confirm the results of this study. Expand
Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease
TLDR
It is concluded that a centrally active ACE inhibitor, perindopril, may have a beneficial effect on Alzheimer's disease as well as hypertension. Expand
Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial.
TLDR
A 12-month double blind randomized clinical trial comparing candesartan, lisinopril, and HCTZ in hypertensives with early executive dysfunction found that an ARB-based regimen would be superior to other antihypertensive regimens in cognitive protection, especially executive function. Expand
Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression
TLDR
The hypothesis that treatment with brain-penetrating ACE inhibitors would slow the rate of cognitive decline in mild-to-moderate AD patients with hypertension is tested. Expand
Effects of cardiovascular medications on rate of functional decline in Alzheimer disease.
  • P. Rosenberg, M. Mielke, +10 authors C. Lyketsos
  • Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2008
TLDR
Use of statins and beta-blockers was associated with delay of functional decline and further studies are needed to confirm these results and to determine whether treatment with these medications may help delay AD progression. Expand
Angiotensin as a target for the treatment of Alzheimer’s disease, anxiety and depression
  • P. Gard
  • Medicine
  • Expert opinion on therapeutic targets
  • 2004
TLDR
These findings suggest that angiotensin receptor ligands may have potential in the prevention or even reversal of vascular dementias and AD and the use of such agents in the treatment of hypertension coexisting with depression or anxiety. Expand
The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis?
TLDR
Current knowledge is reviewed as to the eligibility of ACE-inhibitors and ARAs for consideration in future clinical trials in AD to help ameliorate co-morbid hypertension and help deteriorating cognitive function. Expand
...
1
2
3
4
5
...